The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.70
Bid: 79.90
Ask: 83.90
Change: 0.00 (0.00%)
Spread: 4.00 (5.006%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 82.70
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of public tender offer for Biosearch Life

8 Jul 2021 07:00

RNS Number : 5387E
Kerry Group PLC
08 July 2021
 

 

Date: 8 July 2021

 

LEI: 635400TLVVBNXLFHWC59

 

 

KERRY GROUP

 

Kerry Group plc announces the result of its public tender offer for Biosearch Life

Kerry Group plc ("Kerry"), the global taste & nutrition company, hereby announces the successful result of its public tender offer through its Spanish subsidiary Kerry Iberia Taste & Nutrition, S.L.U on Biosearch, S.A. ("Biosearch"). Following expiry of the acceptance period on June 29th, 52,121,923 Biosearch shares were tendered into the offer, representing 90.33% of the share capital of Biosearch. The result of the offer was approved by the Spanish National Securities Markets Commission on July 5th, 2021 and the acquisition of the shares tendered will be settled today July 8th, 2021.

As anticipated in the offer document and given all necessary conditions are met, Kerry will compulsorily acquire all the remaining shares of Biosearch which have not yet been tendered. The compensation paid will be equal to the price of the tender offer, i.e. €2.20 per share. The total consideration for the transaction is €126.9m.

Biosearch is a leading biotechnology company focused on providing innovative solutions for the pharmaceutical, nutraceutical and functional food sectors. Based in Granada, Spain, the company provides an extensive range of probiotics with leadership in premium probiotics obtained from human breast milk (Hereditum® brand), scientifically backed innovative botanical extracts (Exxentia®) and natural omega-3 (Eupoly-3® brand).

Edmond Scanlon, CEO of Kerry, commented: We have significantly advanced our capabilities in proactive nutrition in recent years. Biosearch is a strong complement to our portfolio and brings leading clinical research capabilities and functional food technologies across multiple life stages and need states. We share a commitment to advance the science behind healthier food and I would like to extend a warm welcome to the Biosearch team."

ENDS

 

About Kerry Group

Kerry is the world's leading taste and nutrition partner for the food, beverage and pharmaceutical industries. We innovate with our customers to create great tasting products, with improved nutrition and functionality, while ensuring better impact for the planet. Our leading consumer insights, global RD&A team of 1,000+ food scientists and local manufacturing footprint in 31 countries enable us to co-create with our customers across over 150 countries. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and will reach over 2 billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerrygroup.com.

About Biosearch Life

Biosearch Life is a leading biotechnology company providing innovative solutions worldwide in the pharmaceutical, nutraceutical and functional food sectors with a workforce of over 150 employees. Biosearch distributes its products across Europe, Asia and the USA and had revenue of €25.3m in 2020. It provides a wide range of high-quality products and services which revolve around the concept of a healthy life with products in three primary areas: probiotics, botanical extracts, and omega-3 fatty acids.

 

 

 

CONTACT INFORMATION

 

 

 

 

 

Investor Relations

 

 

Marguerite Larkin, Chief Financial Officer

 

 

+353 66 7182292 | investorrelations@kerry.ie

 

 

 

 

 

William Lynch, Head of Investor Relations

 

 

+353 66 7182292 | investorrelations@kerry.ie

 

 

 

 

 

Media

 

 

Catherine Keogh, Chief Corporate Affairs & Brand Officer

 

 

+353 45 930188 | corpaffairs@kerry.com

 

 

 

 

 

Website

 

 

www.kerrygroup.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQFLFLTDSIDIIL
Date   Source Headline
3rd May 202412:10 pmRNSKerry Announces €300m Share Buyback Programme
2nd May 20244:14 pmRNSResult of AGM
2nd May 20247:00 amRNSQ1 Interim Management Statement 2024
1st May 202410:05 amRNSTotal Voting Rights
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 202412:42 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20249:48 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 202411:55 amRNSNotice of AGM
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 202410:30 amRNSAnnual Financial Report
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 202412:42 pmRNSDirector/PDMR Shareholding
7th Mar 202412:39 pmRNSDirector/PDMR Shareholding
7th Mar 202412:34 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.